prikaz prve stranice dokumenta Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome
  Download
PDF 184.26 KB
Scientific paper - Case study
Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome
Acta Dermatovenerologica Croatica, 26 (2018), 2; 173-178. urn:nbn:hr:184:217748
Saint-Georges, Valentina; Peternel, Sandra; Kaštelan, Marija; Brajac, Ines

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Saint Georges, V., Peternel, S., Kaštelan, M. & Brajac, I. (2018). Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Acta Dermatovenerologica Croatica, 26. (2), 173-178. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:217748

Saint Georges, Valentina, et al. "Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome." Acta Dermatovenerologica Croatica, vol. 26, no. 2, 2018, pp. 173-178. https://urn.nsk.hr/urn:nbn:hr:184:217748

Saint Georges, Valentina, Sandra Peternel, Marija Kaštelan and Ines Brajac. "Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome." Acta Dermatovenerologica Croatica 26, no. 2 (2018): 173-178. https://urn.nsk.hr/urn:nbn:hr:184:217748

Saint Georges, V., et al. (2018) 'Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome', Acta Dermatovenerologica Croatica, 26(2), pp. 173-178. Available at: https://urn.nsk.hr/urn:nbn:hr:184:217748 (Accessed 27 December 2024)

Saint Georges V, Peternel S, Kaštelan M, Brajac I. Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Acta Dermatovenerologica Croatica [Internet]. 2018 [cited 2024 December 27];26(2):173-178. Available at: https://urn.nsk.hr/urn:nbn:hr:184:217748

V. Saint Georges, S. Peternel, M. Kaštelan and I. Brajac, "Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome", Acta Dermatovenerologica Croatica, vol. 26, no. 2, pp. 173-178, 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:217748. [Accessed: 27 December 2024]

Metadata
Title (english)Tumor necrosis factor antagonists in the treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome
AuthorValentina Saint-Georges
AuthorSandra Peternel
AuthorMarija Kaštelan
AuthorInes Brajac
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Dermatovenerology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Dermatovenerology
Abstract (english)
The clinical triad of pyoderma gangrenosum (PG), acne and suppurative hidradenitis (HS) has been described under the acronym PASH syndrome and is considered to represent a distinct entity in the group of autoinflammatory diseases. It is a fairly new, only recently recognized disorder with a limited number of reported cases and without defined treatment recommendations. We aimed to summarize currently available data on the use of tumor necrosis factor (TNF) antagonists in the management of PASH syndrome and report on our own experience with the use of adalimumab in a patient presenting with this specific constellation of clinical signs and symptoms. Among the 11 cases identified in the literature, infliximab and adalimumab were the most commonly used agents, both exhibiting favorable effects in the majority of, but not all, patients. This was particularly evident in terms of relatively rapid remission of PG whereas HS lesions seemed to be more resistant to treatment. In our patient, adalimumab monotherapy resulted in a remarkable and sustained remission, although significant improvement of HS lesions was observed only from week 16 of therapy onwards. In summary, TNF antagonists are a promising treatment for PASH ; however, conclusions regarding the choice of a specific agent, optimal dosing or use in combination with other treatment modalities cannot yet be drawn.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleActa Dermatovenerologica Croatica
Numberingvol. 26, no. 2, pp. 173-178
p-ISSN1330-027X
e-ISSN1847-6538
URN:NBNurn:nbn:hr:184:217748
Publication2018
Document URLhttp://bib.irb.hr/888271
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2022-03-14 11:39:04